← back to picks
HQ Miryang · South Korea · founded 1984 Listing KRX/KOSPI · 017960 Reporting KRW Structure founder-controlled (Cho family ~58%) Damodaran FCFF · 1000-iter MC FCFF · Dark v3

A cyclical at peak, priced as a secular grower · −20.4% margin of safety

Market sits above the DCF, near the MC p75

Hankuk Carbon is one half of a genuine global duopoly in LNG-carrier cryogenic insulation, riding a finite Qatar/Europe newbuild super-cycle. The through-cycle DCF — built deliberately off normalized mid-cycle margins, not the FY2025 14.4% peak — lands at ₩25,657/share post-governance, 20.4% below the ₩32,250 price. The market is paying for the cycle as if it were permanent: even with year-10 EBIT modelled 34% above the FY2025 peak, the stock still prices rich, and 88% of 1,000 Monte Carlo draws land below today's price. The robustness of the bearish read — not the precise number — is the call. Effective stance: Watchlist / Pass, not buy, at ₩32,250.

p5 ₩20.0k p25 ₩23.2k p50 ₩26.0k p75 ₩29.5k p95 ₩35.0k DCF ₩25.7k MARKET ₩32.3k
SectorChemical (Specialty) · cryogenic insulationMoatMark-III LNG duopoly w/ Dongsung FinetecCountry mix~95% South Koreaβ / MC σ1.08 levered · ±₩4.5k/sh (1000 runs)GovernanceCho family ~58% · 12% residualCaveatcyclical at peak · 88% of draws below price
Intrinsic / share
₩25,656.50
post 12% gov · pre ₩29155.12
Market / share
₩32,250.00
2026-05-29 close · mid-drawdown −34.9% MoM
Margin of safety
-20.4%
vs intrinsic
Enterprise value
₩1.38T
77.3% terminal
Cost of equity / debt
8.66% / 2.91%
β 1.08 · CRP 0.63%
Terminal ROIC / g
13.00% / 3.00%
spread ~457bp (ROIC 13.00% vs WACC 8.43%)

What it sells, where it sells

Operating segments

₩908.8B FY25 revenue
LNG-carrier cryogenic insulationMark-III foam + glass-fibre + triplex barriers holding LNG at −163°C; spec'd into the ship and class-certified, so switching costs are prohibitive — the moat and the whole thesis~85%
Carbon-fibre / composites & prepregAerospace, defence, sports/leisure, EV wheels (Dymag 2023 stake) — a competitive also-ran vs Toray/Hexcel, an optionality kicker, not the thesis~15%

This is a single-engine business: ~85% of revenue is LNG-carrier insulation booked to just three Korean shipyards, so the entire DCF is a bet on one number — the through-cycle operating margin on that one product line — not on the composites side-show.

Country mix (revenue-weighted CRP input)

🇰🇷South Korea95%
🇺🇸United States3%
🇬🇧United Kingdom2%

Near-pure South Korea risk: ~97% of sales are booked in KRW to the three Korean shipyards (HD Hyundai Heavy, Samsung Heavy, Hanwha Ocean). The global LNG demand cycle is the growth driver but lives in the cash flows, not the country-risk premium — so the CRP add-on is just South Korea's 0.64% over the US mature ERP, with the tiny US/UK composites tails near-inert for the WACC.

Background — five things to know before the case

Context the share price doesn't carry on its face. Skim this once and the bull / bear bullets below stop reading as inside baseball.

Where we diverge from the sector

Each row asks: if we'd used the sector median for this one assumption instead of our override, how much would the share price change? Negative = our override is more conservative (worth less); positive = more aggressive (worth more). Skim down the rightmost column to see which bets are doing the work.

Assumption
Our input
Sector median
Value impact
01Revenue growthY1-5 rate, decaying to terminal
7.5% → 3.0%Backlog-anchored deceleration (₩1.75T book ≈ 2x revenue); deliberately well below the FY23-25 +61/+25/+22% ramp the digest flags as the bull trap
~5%Chemical (Specialty), global cross-sector median
modest +
02Operating marginYear-10 target vs sector median EBIT margin — THE CRUX
10.0%Normalized mid-cycle, inside the documented 2.8%–18.4% range; council-revised down from 11% so the model does not eat the FY2025 14.4% peak
12.17%Chemical (Specialty) global median EBIT margin
conservative
03Sales-to-capitalReinvestment efficiency, Y1-5 → Y6-10
1.1 → 1.4Capex/working-capital-heavy ramp (₩40bn CB-funded build, FCF negative in ramp quarters); efficiency rises as the build-out completes
1.105Chemical (Specialty) global median
small
04Terminal growthYear 10+ steady state vs the risk-free ceiling
3.0%At/just below the KRW 10-year risk-free — the Damodaran hard ceiling; a mature cyclical cannot perpetually outgrow the Korean economy
~3.0%Risk-free ceiling, by construction
no-op
05Cost of capital (β)Levered β / WACC vs the suppressed regression β
β 1.08 · WACC 8.43%β_u 1.0428 (sector) re-levered at the net-cash D/E; the 5Y regression β ~1.05 is a boom-dominated window that likely understates a violent cyclical
β ~1.055Y regression β — boom-window, illiquidity-flattered
small −
Net effect of overrides
The overrides are dominated by one line: the 10% normalized margin (well below the 12.17% sector median and the 14.4% FY2025 peak), which is the entire conservative bet. Even with it, year-10 EBIT (₩175.7B) lands 34% above the FY2025 peak EBIT (₩131.0B) — so this is not a pessimistic model, and the stock still prices above the DCF. The robustness of the bearish read, not the precise ₩25,657, is the call.
net conservative
Our override Sector median Adds value Subtracts value

The story & the five claims

The 10-year story this DCF is built on, plus the five anchor claims that translate the story into engine inputs.

The 10-year story

Hankuk Carbon is a wide-moat materials maker that supplies one critical part — the cryogenic insulation that keeps liquefied gas at minus-163 degrees inside an LNG carrier's tanks — to the three Korean shipyards that build most of the world's LNG ships. With one rival, Dongsung Finetec, it splits more than 90% of the licensed market, and that position is hard to attack because the insulation is designed into the ship and certified by safety regulators. The catch is that the business is violently cyclical: its profit margin has swung between 3% and 18% over the past decade, and right now it sits near the top of that range on a post-Ukraine, post-Qatar wave of new ship orders. Our base case is deliberately not that the wave continues forever — it is that revenue keeps converting the roughly ₩1.75 trillion order backlog at high-single-digit growth for a few years, then slows toward replacement demand, while the profit margin settles back to a normalized 10% (below the 12% industry average and well below today's 14.4% peak). On those through-cycle assumptions the company is worth about ₩25,657 a share after a 12% governance discount for the family's control and a real dilution record. That is below the ₩32,250 market price — the market is paying for the peak as if it were permanent.

Two debates worth pressure-testing

What through-cycle margin do you terminal?
Our view: 10%, not the FY2025 14.4% peak. The 10-year record swings 2.8%–18.4%; the revenue-weighted blend lands near 9.7%, so even 11% (the narrative's first pass) had the model quietly eating the peak. The council revised it to 10% — above the FY2016-19 commodity plateau, just under the 12.17% sector median. This single knob is the whole bet: terminal the peak and it's a buy; terminal mid-cycle and it's overvalued.
Is the bearish read robust or fragile?
Our view: Robust. The decisive stress test: year-10 EBIT in the model (₩175.7B) is already 34% above the all-time FY2025 peak EBIT (₩131.0B), and the stock still prices above the DCF. So the overvaluation does not depend on a pessimistic forecast — it survives a generous one. 88% of 1,000 Monte Carlo draws land below today's price.
CLAIM 01Revenue converts backlog, it does not extrapolate the ramp.rev growth 7.5% Y1-5 → 3.0% terminal₩1.75T backlog (≈2x revenue) and yard books to 2027-28 support strong near-term conversion, set well below the FY23-25 +61/+25/+22% prints the digest flags as the primary bull trap. Decays to replacement demand.
CLAIM 02Year-10 margin normalizes to 10%, not the 14.4% peak.target_op_margin 0.10 (council-revised from 0.11)Inside the documented 2.8%–18.4% range and just under the 12.17% sector median. The load-bearing input: terminal the peak and it's cheap; terminal mid-cycle (here) and it's dear.
CLAIM 03Asset-heavy ramp keeps reinvestment efficiency low.sales-to-capital 1.1 (Y1-5) → 1.4 (Y6-10)A ₩40bn CB funded the LNG-line build-out; capex ~₩8.4bn/qtr and FCF went negative in ramp quarters. The model must not assume asset-light efficiency; turns rise only as the build completes.
CLAIM 04Late cyclical normalization — convergence by year 8.year_of_convergence 8 · terminal ROC capped 13%A violent cyclical normalizes later than a steady grower (Nike's 5). Excess returns persist on the duopoly moat but compress off the 20%+ peak toward a ~13% mid-band cap, still above the ~8.4% WACC.
CLAIM 05Terminal growth pinned at the risk-free ceiling; no failure tail.terminal g 3.0% · failure prob 0% · gov 12%g at/just below the KRW 10y risk-free; net-cash balance sheet means no going-concern failure. Governance carried in the flows, leaving a 12% residual for dilution/CB-conversion leakage.
Where we diverge from sell-side
  • We terminal mid-cycle, the Street terminals the peak. Consensus models double-digit growth and ~14% margins persisting; we fade growth to 3% and the margin to a normalized 10%, refusing to extrapolate the FY2025 cyclical high.
  • Earnings quality flagged. FY2025 profit carried a ~₩15bn unusual-item boost and Q1-2026 net income actually fell YoY (₩15.5B vs ₩21.9B) — statutory earnings likely overstate ongoing power, which the conservative margin captures.
  • FCF, not net income, governs. Strong profit but FCF turned negative on capacity capex and working-capital build; we hold sales-to-capital at the asset-heavy 1.1 in the ramp rather than crediting clean conversion.
  • Governance in the flows, 12% residual. The ~17% dilution record is the real charge, partly offset by the ₩11.4bn treasury cancellation; we price leakage/dilution at 12%, not a flat end-of-model Korea haircut.
  • β re-levered from the sector, not the boom-window regression. The 5Y regression β ~1.05 sits inside a cycle up-leg and likely understates a violent cyclical; we re-lever the sector β_u 1.0428 to 1.08 and let wide MC bands carry the cyclical risk.
Two-sided case — bear anchors
  • The newbuild wave rolls over. If the super-cycle matures faster than modelled (ammonia/hydrogen marine fuel displacing LNG newbuilds), growth fades to 3-5% and the margin to the 5-7% FY2018/FY2024 plateau — a downside scenario worth far less than the base case.
  • Margin reverts harder than 10%. The crux cuts both ways: the FY2023 trough was 2.8% with a net loss. A genuine cyclical trough mid-forecast would gut the terminal value, which is already 76% of enterprise value.
  • Further dilutive issuance. The capex/working-capital ramp has historically been funded with discounted equity and convertibles; another round to fund capacity would compound the ~17% dilution already on the record.
  • Customer concentration is absolute. ~97% of sales route through three Korean shipyards; an order-book slip at any one (a Qatari project slipping, a yard losing share) transmits straight to Hankuk with no diversification cushion.
  • It is already priced as a grower. Trailing P/E ~24, forward ~20 vs KR Chemicals ~17; the screener rule flags it. Even the bull DCF (11% margin / super-cycle structural) barely clears today's price — the asymmetry is poor.

Risks to thesis (tail, not bear case)

Cyclical margin reversionHigh

The defining risk. The 10-year op-margin record is 2.8%–18.4%; a genuine trough mid-forecast (FY2023 saw 2.8% and a net loss) would gut a terminal value that is already 76% of enterprise value. The 10% normalized margin is the single load-bearing assumption.

Super-cycle ends earlyHigh

The LNG newbuild wave is finite. If ammonia/hydrogen marine fuel displaces LNG carriers faster than expected — only partly hedged by those fuels also needing cryogenic containment — the backlog-anchored growth fades and replacement demand undershoots 3%.

Dilutive issuanceMed

Shares grew ~17% FY2020-25, much during loss years, with a live risk of further discounted equity/CB issuance to fund the capex ramp. The 12% governance residual prices this; a worse outcome justifies more.

Earnings-quality overstatementMed

FY2025 profit carried a ~₩15bn unusual-item boost; Q1-2026 net income fell YoY. If reported margins flatter the run-rate, the cyclical-peak base year is even more of a trap than modelled.

Customer concentrationLow

~97% of sales route through three Korean shipyards. Structurally a feature of the duopoly, but a slip at any one yard transmits directly with no diversification cushion.

Suppressed-beta cyclical riskLow

The 5Y regression β ~1.05 sits inside a boom window and likely understates a violent cyclical. We re-lever the sector β_u and lean on wide MC bands (±₩4.5k/sh) rather than an inflated beta to carry the risk.

10-year forecast

Revenue ₩977.0B → ₩1.76T over 10y (7.5% fading to 3.0% terminal); operating margin steps down from the FY2025 14.4% peak toward a normalized 10% by year 8, the deliberate refusal to terminal the peak. Even so, year-10 EBIT (₩175.7B) sits 34% above the FY2025 peak EBIT (₩131.0B).

Y1 Y2 Y3 Y4 Y5 Y6 Y7 Y8 Y9 Y10 0 1.8T rev (KRW) 0% 15% op margin revenue FCFF op margin

Monte Carlo distribution

Across 1,000 correlated stress draws the median outcome is ₩25,963/share and even the 75th percentile (₩29,468) sits below today's ₩32,250 price — 88% of all draws land below the market, and only the top ~12% (toward the ₩34,977 p95, where the super-cycle holds and the margin runs hot) clear it. The distribution says the disagreement is how overvalued, not whether.

p5 p25 p50 p75 p95 market 32250.00 16782.6 25963.1 41062.4 freq equity / share (KRW)

Mean ₩26588.24 ± ₩4485.13/sh, 1000 iterations (0 failed). P(intrinsic < market ₩32250.00) = 88.0%.

Cost of capital build
Risk-free rate 3.43%
Mature-market ERP 4.23%
Levered β 1.08
Weighted CRP 0.63%
Cost of equity 8.66%
Pre-tax cost of debt (synth Aaa/AAA) 3.83%
D / V ~4%
WACC 8.43%
Full year-by-year DCF
Year Revenue Op mgn EBIT EBIT(1−t) Reinvest FCFF PV
1 ₩976.97B 13.86% ₩135.39B ₩104.47B ₩61.96B ₩42.50B ₩39.20B
2 ₩1.05T 13.31% ₩139.75B ₩107.83B ₩66.61B ₩41.22B ₩35.06B
3 ₩1.13T 12.76% ₩144.01B ₩111.12B ₩71.61B ₩39.51B ₩31.00B
4 ₩1.21T 12.20% ₩148.12B ₩114.29B ₩76.98B ₩37.32B ₩27.00B
5 ₩1.30T 11.65% ₩152.04B ₩117.32B ₩82.75B ₩34.57B ₩23.06B
6 ₩1.40T 11.10% ₩155.72B ₩119.79B ₩69.90B ₩49.89B ₩30.71B
7 ₩1.51T 10.55% ₩159.09B ₩122.01B ₩75.14B ₩46.87B ₩26.60B
8 ₩1.62T 10.00% ₩162.08B ₩123.94B ₩80.77B ₩43.16B ₩22.59B
9 ₩1.71T 10.00% ₩170.59B ₩130.05B ₩60.78B ₩69.27B ₩33.59B
10 ₩1.76T 10.00% ₩175.71B ₩133.54B ₩36.56B ₩96.98B ₩43.75B
Methodology & flags

Damodaran FCFF DCF, 10y explicit + perpetuity, in KRW. Risk-free 3.43% (local-currency government bond). Synthetic credit Aaa/AAA. CRP 0.63% from revenue-weighted country mix × Damodaran 2026 CRPs. Terminal ROIC faded to 13.00%; 12% governance haircut applied post-DCF. Monte Carlo: 1000 iterations. Engine v1.0.0 · result: /Users/valentin/Documents/notes_jiliac_labs/Finance/Damodaran/valuations/hankukcarbon/output/2026-06-01-result.json

  • R&D cap: OFF · Lease cap: OFF · Failure: OFF · ESO: OFF
  • Governance haircut: 12% applied post-DCF (₩29155.12 > ₩25656.50)
  • Sensitivity tornado: not run